Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.
2.

In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.

Oliveira AD, D'Azevedo PA, Francisco W.

Cornea. 2007 Feb;26(2):194-8.

PMID:
17251812
3.

[Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].

Hidalgo M, Reyes J, Cárdenas AM, Díaz L, Rincón S, Vanegas N, Díaz PL, Castañeda E, Arias CA.

Biomedica. 2008 Jun;28(2):284-94. Spanish. Erratum in: Biomedica. 2008 Sep;28(3):460.

4.

Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.

Scoper SV.

Adv Ther. 2008 Oct;25(10):979-94. doi: 10.1007/s12325-008-0107-x. Review.

PMID:
18836691
5.

Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.

Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ.

Am J Ophthalmol. 2003 Sep;136(3):500-5.

PMID:
12967804
6.

Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.

Reddy AK, Garg P, Alam MR, Gopinathan U, Sharma S, Krishnaiah S.

Eye (Lond). 2010 Jan;24(1):170-4. doi: 10.1038/eye.2009.29. Epub 2009 Feb 20.

PMID:
19229279
8.

The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.

Park SH, Lim JA, Choi JS, Kim KA, Joo CK.

Cornea. 2009 Jan;28(1):68-72. doi: 10.1097/ICO.0b013e318182259b.

PMID:
19092409
9.

In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.

Stroman DW, Dajcs JJ, Cupp GA, Schlech BA.

Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. Review.

PMID:
16257308
10.

[In vitro antibiotic susceptibility to fluoroquinolones].

Wong CA, Galvis V, Tello A, Villareal D, Rey JJ.

Arch Soc Esp Oftalmol. 2012 Mar;87(3):72-8. doi: 10.1016/j.oftal.2011.06.023. Epub 2011 Dec 29. Spanish.

PMID:
22423655
11.

Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).

Schlech BA, Alfonso E.

Surv Ophthalmol. 2005 Nov;50 Suppl 1:S7-15. Review.

PMID:
16257313
12.

In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.

Yamada M, Hatou S, Yoshida J.

Eye Contact Lens. 2008 Mar;34(2):109-12. doi: 10.1097/ICL.0b013e31813c102a.

PMID:
18327047
13.

Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.

Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H.

Adv Ther. 2003 Sep-Oct;20(5):246-52.

PMID:
14964344
14.

[Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].

Wang ZQ, Li L, Li R, Luo SY, Bai XQ, Liang QF, Deng SJ, Sun XG.

Zhonghua Yan Ke Za Zhi. 2008 Mar;44(3):233-6. Chinese.

PMID:
18785547
15.

Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.

Mather R, Karenchak LM, Romanowski EG, Kowalski RP.

Am J Ophthalmol. 2002 Apr;133(4):463-6.

PMID:
11931779
16.

[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].

Hoepelman I.

Ned Tijdschr Geneeskd. 2004 Oct 23;148(43):2115-21. Review. Dutch.

PMID:
15553354
17.

[In vitro fluoroquinolone resistance in ocular bacterial isolates].

Sun XG, Wang ZQ, Li R, Chen L, Jin XY, Luo SY.

Zhonghua Yan Ke Za Zhi. 2003 Mar;39(3):163-6. Chinese.

PMID:
12880574
19.

An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.

Kowalski RP, Yates KA, Romanowski EG, Karenchak LM, Mah FS, Gordon YJ.

Ophthalmology. 2005 Nov;112(11):1987. Epub 2005 Sep 23.

PMID:
16183128

Supplemental Content

Support Center